Advertisement

Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women

      Abstract

      The contraceptive efficacy and safety of a progesterone-releasing vaginal ring (PVR) manufactured in Chile were compared to that of the Copper T 380A IUD (T-Cu) in nursing women enrolled at three Chilean clinics. A total of 285 volunteers chose to use the PVR and 262 the T-Cu. Plasma progesterone levels attained with the ring decreased from 25 to 14 nmol/L from month 1 to month 3 of use. Ring replacement was scheduled every 3 months. Volunteers continued in the study until weaning or completing the continuous use of four PVRs. No pregnancies occurred in 2320 and 2183 woman-months of exposure with the PVR and the T-Cu, respectively. Lower continuation rates in the first 6 months because of problems with use and a longer lactational amenorrhea were observed in the PVR than in the T-Cu group. Breast-feeding performance and infant growth were similar in both groups. These results confirm the high efficacy and safety of the PVR for nursing women and have led to the registration of the PVR by Chilean health authorities.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. International Planned Parenthood Federation: Statement on Breast Feeding, Fertility and Post-Partum Contraception. Statement by the International Medical Advisory Panel, November 1989, 1–5.

        • Dı́az S
        • Croxatto H.B
        Contraception in lactating women.
        Curr Opin Obstet Gynecol. 1993; 5: 815-822
      2. World Health Organization. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 1996.

        • Hull V.J
        The effects of hormonal contraceptives on lactation.
        Stud Fam Plan. 1981; 12: 134-155
        • Peralta O
        • Dı́az S
        • Juez G
        • et al.
        Long-term influence of a low-dose combined oral contraceptive initiated at day 90 postpartum upon lactation and infant growth.
        Contraception. 1983; 27: 27-38
        • World Health Organization
        Task Force on Oral Contraceptives. Effects of hormonal contraceptives on milk volume and infant growth.
        Contraception. 1984; 30: 505-521
        • World Health Organization
        Task Force on Oral Contraceptives. Special Programme of Research, Development and Research Training in Human Reproduction. Effects of hormonal contraceptives on breast milk composition and infant growth.
        Stud Fam Plan. 1988; 19: 361-369
        • World Health Organization
        Task Force for Epidemiological Research on Reproductive Health. Special Programme of Research, Development and Research Training in Human Reproduction. Progesterone-only contraceptives during lactation.
        Contraception. 1994; 50: 35-53
        • World Health Organization
        Task Force for Epidemiological Research on Reproductive Health. Special Programme of Research, Development and Research Training in Human Reproduction. Progesterone-only contraceptives during lactation.
        Contraception. 1994; 50: 55-68
      3. McCann MF, Potter LS. Effects of POPs on breastfeeding. In: Progestin-only oral contraception: a comprehensive review. Contraception 1994;50 (suppl 1):140–8.

        • Whitehead M.I
        • Townsend P.T
        • Gill D.K
        • Collins W.P
        • Campbell S
        Absorption and metabolism of oral progesterone.
        Br Med J. 1980; 80: 825-827
        • Dı́az S
        • Jackanicz T.M
        • Herreros C
        • et al.
        Fertility regulation in nursing women.
        Contraception. 1985; 32: 603-622
        • Sivin I, D
        • ı́az S
        • Croxatto H
        • et al.
        Contraceptives for nursing women.
        Contraception. 1997; 55: 225-232
      4. Sánchez S, Araya C, Tijero M, Dı́az S. Women’s perceptions and experience with the progesterone vaginal ring for contraception during breastfeeding. In: Beyond Acceptability: User’s Perspectives on Contraception. London: Reproductive Health Matters, for World Health Organization, Reproductive Health Matters 1997:49–57.

        • Sufi S.B
        • Donaldson A
        • Jeffcoate S.L
        WHO Matched Reagent Programme Method Manual, 19th ed. World Health Organization, Geneva1995: 36-46
        • Croxatto H.B
        • Dı́az S
        Progesterone vaginal rings for contraception during breastfeeding.
        in: Runnebaum B Rabe T Kiesel L Advances in Gynecological and Obstetric Research Series, Vol. 2. Female Contraception and Male Fertility Regulation. The Parthenon Publishing Group, New Jersey1991: 135-142
        • Dı́az S
        • Zepeda A
        • Maturana X
        • et al.
        Fertility regulation in nursing women. IX. Contraceptive performance, duration of lactation, infant growth, and bleeding pattern during use of progesterone vaginal rings, progestin-only pills, Norplant® implants and Copper T 380-A intrauterine devices.
        Contraception. 1997; 56: 223-232
        • Chen J.H
        • Wu S.C
        • Shao W.Q
        • et al.
        The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
        Contraception. 1998; 57: 371-379
        • Chi I-Ch
        • Potts M
        • Wilkens L.R
        • Champion ChB
        Performance of the Copper T 380A intrauterine device in breastfeeding women.
        Contraception. 1989; 39: 603-618